A belinostat drug co-crystal and its preparation method and application

By forming co-crystals with isoniazid or isonicotinamide, and preparing belista drug co-crystals by grinding or solvent-mediated methods, the problems of low water solubility and poor compliance of belista drugs are solved, and solubility is achieved and the improvement of bioavailability simplifies the preparation process and reduces costs, making it suitable for industrial production.

CN115724775BActive Publication Date: 2024-11-29TIANJIN UNIV
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202211465535.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-22
Publication Date
2024-11-29
Estimated Expiration
2042-11-22

Smart Images

  • Figure CN115724775B_ABST
    Figure CN115724775B_ABST
Patent Text Reader

Abstract

The present invention provides a belinostat drug cocrystal and a preparation method and application thereof, wherein the belinostat drug cocrystal is formed by combining a belinostat drug and a cocrystal ligand in a molar ratio of 1:1, and the cocrystal ligand is isoniazid or isonicotinamide; the method for preparing the drug cocrystal of the present invention is a solution-mediated method or a grinding method, and the two prepared belinostat cocrystals are characterized by means of X-ray powder diffraction (PXRD), single crystal X-ray powder diffraction (SXRD), differential scanning calorimetry (DSC), thermogravimetric analyzer (TGA), etc. The cocrystal of the present invention inherits the pharmacological activity of belinostat itself, and has obvious improvements in its solubility and stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology and relates to a belinostat drug cocrystal and a preparation method and application thereof. Background Art

[0002] In recent years, pharmaceutical cocrystal technology has attracted much attention due to its unique physical and chemical properties. It is a new means to quickly and effectively improve the physical and chemical properties of active pharmaceutical ingredients. The functional groups contained in the active molecules of the drug can combine with other organic molecules in the same crystal lattice to form cocrystals by hydrogen bonding or other non-covalent bonds (such as hydrogen bonding, van der Waals forces, π-π stacking, halogen bonds, etc.), thereby effectively improving the crystallization performance, stability, solubility, dissolution, bioavailability and efficacy of the drug itself, becoming a new choice for solid pharmaceutical preparations. Pharmaceutical cocrystals provide more options for dosage form design, can extend the market cycle of the original drugs, and show potential application prospects in the fields of pharmacology and biomedicine.

[0003] Belinostat is a BCS Class II drug, which is limited by its low water solubility (0.14 mg / mL). It is currently sold in the market in the form of sterile lyophilized powder injection for intravenous injection. The FDA recommended dose is 1000 mg / m 2 , administered by intravenous infusion over 30 minutes once daily on days 1-5 of a 21-day cycle, with the cycle repeated every 21 days.

[0004] In order to improve the water solubility of belinostat and increase patient compliance, a variety of oral preparations of belinostat have been developed. CN107698632A discloses a belinostat derivative based on acetic acid, which uses acetic acid to replace the terminal hydroxamic acid functional group, but uses tetrahydrofuran and pyridine belonging to Class I and Class II solvents, which have certain toxicity and carcinogenicity. Inhalation of a large amount can cause poisoning, headache, vomiting, and impaired hematopoietic function, posing certain safety hazards; WO2019 / 002614EN has developed a belinostat amorphous solid dispersion, in which belinostat and PVPK30, PVPK12, PVPK25, PVPK90, PVPVA64 and a mixture thereof are prepared by spray drying, but the amorphous solid dispersion itself is unstable and easily converted into crystals, and the spray drying equipment is complex; WO2018 / 020406 EN discloses a method for preparing a polymorph of belinostat, in which a polar protic solvent is added to belinostat and an acetone solvent, and an anti-solvent is added for separation and drying to prepare a belinostat acetone solvate. The inventors prepared the product according to the patented method, but failed to obtain belinostat solvate, which has poor reproducibility, complicated operation and is not conducive to industrial scale-up.

[0005] In order to improve the quality of drugs and solve the problems of low water solubility and poor compliance of belinostat, belinostat is used as the active ingredient of the drug to find a suitable cocrystal ligand, which can effectively improve its solubility and dissolution rate. There is no report on belinostat drug cocrystals. Summary of the invention

[0006] In order to overcome the deficiencies of the prior art, the purpose of the present invention is to provide a belinostat drug cocrystal and a preparation method and application thereof, wherein the drug belinostat is cocrystaled with a cocrystal ligand isoniazid or isoniazid, which has a significant effect on the physicochemical properties of the active drug ingredients without changing the covalent structure of the active drug component belinostat, thereby improving the bioavailability of the drug and enhancing the efficacy of the drug.

[0007] One of the purposes of the present invention is to provide a belinostat drug co-crystal, wherein the belinostat drug co-crystal is formed by combining a belinostat drug and a co-crystal ligand in a molar ratio of 1:1, and the co-crystal ligand is isoniazid or isonicotinamide.

[0008] When the cocrystal ligand is isoniazid, the molecular formula of the belinostat drug cocrystal is C 21 H 21 N5O5S;

[0009] Preferably, using Cu-kα radiation, the X-ray powder diffraction pattern of belinostat-isoniazid cocrystal expressed by a diffraction angle 2θ has characteristic diffraction peaks at 18.1±0.2°, 18.5±0.2°, 18.9±0.2°, 19.2±0.2°, 19.9±0.2°, 22.2±0.2°, 22.9±0.2°, 24.0±0.2°, 24.2±0.2°, and 24.5±0.2°.

[0010] Preferably, the belinostat-isoniazid cocrystal is a triclinic system with a space group of The unit cell parameters are α=93.416(1)°,β=100.770(1)°,γ=101.188(1)°;the unit cell volume is Z=2.

[0011] In the present invention, the basic structural unit of the belinostat-isoniazid cocrystal (denoted as cocrystal 1) is composed of a belinostat molecule and a nitrogen atom on the pyridine ring that forms a hydrogen bond to form a one-dimensional chain structure in the direction.

[0012] When the co-crystal ligand is isonicotinamide, the molecular formula of the belinostat drug co-crystal (referred to as co-crystal 2) is C 21 H 20 N4O5S;

[0013] Preferably, the cocrystal ligand is isonicotinamide, and the belinostat drug cocrystal is a triclinic system with a space group of The unit cell parameters are α=96.427(1)°,β=101.025(1)°,γ=99.660(1)°;the unit cell volume is Z=2.

[0014] A second object of the present invention is to provide a method for preparing belinostat drug cocrystals, which comprises a grinding method or a solvent-mediated method.

[0015] When the cocrystal ligand is isoniazid, the preparation method is a grinding method;

[0016] Preferably, the grinding method comprises: adding belinostat and isoniazid in a molar ratio of 1:(0.8-1.3) into a ball mill, adding a small amount of organic solvent, and ball milling to obtain belinostat-isoniazid drug cocrystal.

[0017] Preferably, the ball milling time is 10-60 min, and the ball milling frequency is 15-30 Hz;

[0018] Preferably, the organic solvent is any one of ethanol, isopropanol, acetone or ethyl acetate, or a combination of at least two thereof;

[0019] Preferably, based on 1 g of belinostat, the amount of the organic solvent added is 0-800 μL.

[0020] When the co-crystal ligand is isonicotinamide, the preparation method is a solvent-mediated method;

[0021] Preferably, the solvent-mediated method comprises: mixing belinostat and isonicotinamide in a molar ratio of 1:(0.8-1.2), adding an organic solvent, and reacting at 25-40° C. for 12-48 hours to obtain belinostat-isonicotinamide cocrystal.

[0022] Preferably, the organic solvent comprises any one or a combination of at least two of isopropanol, acetonitrile or ethyl acetate;

[0023] Preferably, based on 1 g of belinostat, the amount of the organic solvent added is 10-60 mL.

[0024] Preferably, the preparation method further comprises sequentially performing solid-liquid separation and drying on the mixture obtained after the reaction.

[0025] The third object of the present invention is to provide a use of the belinostat drug co-crystal as described in the first object in the preparation of targeted drugs.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] The co-crystal prepared by the present invention is prepared by a method of slow volatilization of the solvent at room temperature and a liquid phase assisted grinding method. These two methods are simple and easy to operate, convenient for large-scale promotion in industrial pharmaceuticals, and low in cost.

[0028] 1. The present invention adopts a grinding or solvent-mediated method to prepare two belinostat drug co-crystals, which has simple process, mild conditions, good repeatability, green and environmental protection, and is suitable for large-scale production.

[0029] 2. The belinostat drug co-crystal of the present invention can effectively modify the active ingredients of the drug. In addition to maintaining the therapeutic properties of belinostat itself, its physicochemical properties such as solubility, stability and bioavailability are improved to a certain extent. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Powder X-ray diffraction patterns of the active pharmaceutical ingredient belinostat, the cocrystal precursor isoniazid and the belinostat drug cocrystal 1 provided by the present invention.

[0031] Figure 2 Powder X-ray diffraction patterns of the active pharmaceutical ingredient belinostat, the cocrystal ligand isonicotinamide, and the belinostat drug cocrystal 2 provided by the present invention.

[0032] Figure 3 The crystal structure diagram of the belinostat drug cocrystal 1 provided by the present invention.

[0033] Figure 4 The crystal structure diagram of the belinostat drug cocrystal 2 provided by the present invention.

[0034] Figure 5 The thermal analysis spectrum of the belinostat drug cocrystal 1 provided by the present invention includes a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum.

[0035] Figure 6 The thermal analysis spectrum of the belinostat drug cocrystal 2 provided by the present invention includes a differential scanning calorimetry (DSC) spectrum and a thermogravimetric analysis (TGA) spectrum.

[0036] Figure 7 The stability test spectrum of the belinostat drug cocrystal 1 provided by the present invention after storage for 180 days.

[0037] Figure 8 The stability test spectrum of the belinostat drug cocrystal 2 provided by the present invention after storage for 180 days.

[0038] Fig. 9 The present invention provides belinostat drug cocrystal 1, belinostat drug cocrystal 2, and belinostat powder dissolution curves suspended for 6 hours in a phosphate buffer solution at pH=6.8. DETAILED DESCRIPTION

[0039] It should be noted that the following detailed descriptions are all exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs. The technical scheme of the present invention is further illustrated below by specific embodiments. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0040] Testing instruments and methods

[0041] 1. The PXRD patterns were measured at ambient temperature using a powder X-ray diffractometer Rigaku D / max 2500 (Rigaku, Japan). The measurement conditions were as follows: scanning range 3.5-40°, scanning rate 8° / min, scanning step length 0.02°, emission target Cu Kα, wavelength The voltage and current were 40 kV and 100 mA respectively.

[0042] 2. The eutectic single crystal obtained in the example was placed in a Rigaku 007HF XtaLAB P200 diffractometer and Mo Kα The crystal structure was solved by the OLEX2 direct method, and the SHELXL-97 program package was used to perform full matrix least squares optimization on F2 to identify the atomic species.

[0043] 3. Differential Scanning Calorimetry (DSC) Experiments Mettler Toledo DSC 1 / 500 was used for testing. 5-10 mg of the drug was placed in a standard aluminum pan and heated at a heating rate of 10°C / min under nitrogen.

[0044] 4. TG analysis was performed using a Mettler TGA / DSC 1stare system. 5-10 mg of the eutectic prepared by the method of the present invention was weighed and placed in a standard alumina crucible, and scanned at a heating rate of 10° C. / min at a nitrogen flow rate of 20 mL / min.

[0045] 5. Liquid chromatography column: Agilent Extend C18 column, 4.6 mm × 250 mm, 5 μm; column temperature: 30 °C; mobile phase: 0.1% phosphoric acid aqueous solution and acetonitrile (60:40% v / v); flow rate: 1 mL / min; injection volume: 10 μL; wavelength: 272 nm.

[0046] Example 1

[0047] 31.8 mg of belinostat solid and 13.7 mg of isoniazid solid were weighed and placed in a ball mill, 20 μL of ethanol was added, and ball milling was performed at a frequency of 15 Hz for 10 min. The obtained product was dried at room temperature to obtain belinostat drug cocrystal 1.

[0048] Example 2

[0049] 96.0 mg of belinostat solid and 41.1 mg of isoniazid solid were weighed and placed in a ball mill, 20 μL of ethyl acetate was added, and ball milling was performed at a frequency of 25 Hz for 15 min to obtain belinostat drug cocrystal 1.

[0050] Example 3

[0051] 0.199 g of Belinostat solid and 0.0822 g of isoniazid solid were weighed and put into a ball mill, 100 μL of isopropanol was added, and the mixture was ball milled at a frequency of 30 Hz for 20 min. After drying at room temperature, a solid sample of Belinostat-drug cocrystal 1 was obtained.

[0052] Example 4

[0053] At 30°C, 31.8 mg of belinostat solid, 12.2 mg of isonicotinamide 122.13 solid and 1 mL of acetonitrile were added to a reaction bottle and stirred for 48 h. The resulting suspension was separated and dried at room temperature for 12 h. The resulting solid was belinostat drug cocrystal 2.

[0054] Example 5

[0055] At 40°C, 0.2786 g of belinostat solid, 0.1024 g of isonicotinamide solid and 9 mL of ethyl acetate were added to a reaction bottle and stirred for 48 h. The resulting suspension was separated and dried at room temperature for 12 h. The resulting solid was belinostat drug cocrystal 2.

[0056] Example 6

[0057] At 30°C, 0.318 g of belinostat solid, 0.122 g of isonicotinamide solid and 12 mL of isopropanol were added to a reaction bottle and stirred for 48 h. The resulting suspension was separated and dried at room temperature for 24 h. The resulting solid was belinostat drug cocrystal 2.

[0058] In the above-mentioned embodiments, the powder X-ray diffraction patterns of the active pharmaceutical ingredient belinostat, the cocrystal precursor isoniazid, and the belinostat drug cocrystal 1 are as follows: Figure 1 , Figure 2 As shown. Figure 1It can be seen that the X-ray powder diffraction of Belinostat drug cocrystal 1 has characteristic peaks at diffraction angles of 6.0°, 11.0°, 12.0°, 12.5°, 13.6°, 15.0°, 16.7°, 18.1°, 18.5°, 18.9°, 19.2°, 19.9°, 21.6°, 22.2°, 22.6°, 22.9°, 24.0°, 24.2°, 24.5°, 25.6°, and 26.6°, which are different from the superposition of the characteristic peaks of the raw material Belinostat and the cocrystal precursor isoniazid, indicating that the prepared substance may be Belinostat drug cocrystal 1. Similarly, the X-ray powder diffraction pattern of Belinostat drug cocrystal 2 is shown in Figure 2 As shown, there are characteristic diffraction peaks at diffraction angles of 12.3°, 12.9°, 13.59°, 14.9°, 16.1°, 16.5°, 18.1°, 19.0°, 19.3°, 19.9°, 22.1°, 23.8°, 24.5°, 24.9°, 25.3°, and 27.1°, which are different from the superposition of characteristic peaks of the raw material belinostat and the cocrystal precursor isonicotinamide, indicating that the prepared substance may be the belinostat drug cocrystal 2.

[0059] The crystal structures of Belinostat drug cocrystal 1 and Belinostat drug cocrystal 2 (see Figure 3 , Figure 4 ) was analyzed, and its crystallographic parameters are shown in Table 1:

[0060] Table 1 Crystallographic parameters of belinostat drug cocrystals

[0061]

[0062]

[0063] The eutectic prepared in the embodiment of the present invention was further analyzed by differential scanning calorimetry (DSC). Figure 5 As shown in the figure, belinostat drug cocrystal 1 has a sharp single peak at 161°C, which is different from the melting point of belinostat at 172°C and the melting point of isoniazid at 170°C, further proving the formation of belinostat drug cocrystal 1; Figure 6 , a sharp single peak appeared at 151 °C for belinostat drug cocrystal 2, which also proved the formation of belinostat drug cocrystal 2.

[0064] The cocrystal prepared in the present invention was subjected to an accelerated stability test. The cocrystal sample was weighed and stored in a desiccator filled with saturated sodium chloride solution at an ambient temperature of 40°C and a relative humidity (RH) of 75%. After 180 days, the sample was weighed and the PXRD pattern was measured. The stability PXRD pattern of the Belinostat drug cocrystal 1 is shown in FIG. Figure 7 As shown in the figure, the stability PXRD pattern of belinostat-drug cocrystal 2 is as follows Figure 8 As shown, the XRD spectra of the two did not change significantly, proving that belinostat drug cocrystal 1 and belinostat drug cocrystal 2 did not undergo any transformation and had good stability.

[0065] The dissolution rates of belinostat, belinostat drug cocrystal 1, and belinostat drug cocrystal 2 were determined by paddle method. The API and cocrystal containing the same molar amount of belinostat were ground and passed through 80 and 160 mesh sieves, respectively, and then added to the dissolution apparatus at a paddle speed of 100 rpm at 37°C. 2 mL of solution was taken out from the container at 1, 3, 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, and 360 min, respectively, and filtered through a 0.45 mm nylon filter, after which the solution concentration was determined by HPLC and analyzed by standard curve.

[0066] The results of the in vitro buffer solution dissolution test of the cocrystal are as follows Fig. 9 As shown, the results show that in a phosphate buffer solution of pH = 6.8, the solubility of the two cocrystals is increased by 1.14-1.17 times relative to the API. Improving the water solubility of the API through drug cocrystal technology is expected to become a breakthrough in the preparation of belinostat solid oral preparations.

[0067] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A belinostat drug cocrystal, characterized in that: The belinostat drug co-crystal is formed by combining the belinostat drug and the co-crystal ligand in a molar ratio of 1:1, and the co-crystal ligand is isoniazid or isonicotinamide; The cocrystal ligand is isoniazid, and the belinostat-isoniazid cocrystal is a triclinic system with a space group of The unit cell parameters are α=93.416(1)°, β=100.770(1)°, γ=101.188(1)°; The unit cell volume is Z = 2; The cocrystal ligand is isoniazid, and the molecular formula of the belinostat drug cocrystal is C 21 H 21 N5O5S; Using Cu-kα radiation, the X-ray powder diffraction pattern of belinostat-isoniazid cocrystal expressed as a diffraction angle 2θ has characteristic diffraction peaks at 18.1±0.2°, 18.5±0.2°, 18.9±0.2°, 19.2±0.2°, 19.9±0.2°, 22.2±0.2°, 22.9±0.2°, 24.0±0.2°, 24.2±0.2°, and 24.5±0.2°; The cocrystal ligand is isonicotinamide, and the belinostat drug cocrystal is a triclinic system with a space group of The unit cell parameters are α=96.427(1)°,β=101.025(1)°,γ=99.660(1)°;the unit cell volume is Z = 2; The co-crystal ligand is isonicotinamide, and the molecular formula of the belinostat drug co-crystal is C 21 H 20 N4O5S.

2. The method for preparing the belinostat drug cocrystal according to claim 1, characterized in that: The co-crystal ligand is isoniazid, and the preparation method is a grinding method; The grinding method comprises: adding belinostat and isoniazid in a molar ratio of 1:(0.8-1.3) into a ball mill, adding a small amount of organic solvent, and ball milling to obtain belinostat isoniazid drug cocrystal; The organic solvent is any one of ethanol, isopropanol, acetone or ethyl acetate, or a combination of at least two of them.

3. The preparation method according to claim 2, characterized in that: The ball milling time is 10-60 min, and the ball milling frequency is 15-30 Hz.

4. The preparation method according to claim 2, characterized in that: Based on the addition amount of belinostat being 1 g, the addition amount of the organic solvent is 0-800 μL.

5. The method for preparing the belinostat drug cocrystal according to claim 1, characterized in that: The co-crystal ligand is isonicotinamide, and the preparation method is a solvent-mediated method; The solvent-mediated method comprises: mixing belinostat and isonicotinamide at a molar ratio of 1:(0.8-1.2), adding an organic solvent, and reacting at 25-40° C. for 12-48 hours to obtain belinostat-isonicotinamide cocrystal; The organic solvent includes any one of isopropanol, acetonitrile or ethyl acetate or a combination of at least two thereof.

6. The preparation method according to claim 5, characterized in that: Based on the addition amount of belinostat being 1 g, the addition amount of the organic solvent is 10-60 mL.

7. The preparation method according to claim 5, characterized in that: The preparation method further comprises sequentially performing solid-liquid separation and drying on the mixture obtained after the reaction.

8. Use of the belinostat drug co-crystal according to claim 1 in the preparation of targeted drugs.

Citation Information

Patent Citations

  • Belinostat derivative based on acetic acid, and preparation method and application thereof

    CN107698632A

  • Isoliquiritigenin pyrazinamide eutectic crystal and preparation method thereof

    CN105622497A

  • Belinostat crystal and preparation method therefor

    CN106565552A

  • Isoniazide, pyrazinamide and fumaric acid ternary eutectic and preparation method thereof

    CN107522655A

  • Isonicotinamide and acipimox eutectic crystal II and preparation method thereof

    CN112110865A